“It is unlikely that B/Yamagata-lineage viruses are circulating in the population. Therefore, it is the opinion of the WHO influenza vaccine composition advisory committee that the inclusion of B/Yamagata-lineage antigens in influenza vaccines is no longer warranted,” the agency said when it released its recommendations for 2024 flu vaccines Sept. 29.
Instead, the WHO is recommending a trivalent vaccine for the 2024 Southern Hemisphere flu season that should target two influenza A viruses — H1N1 and H3N2 — and an influenza B/Victoria virus.
Vaccines for the current flu season in the U.S. still include a Yamagata lineage virus.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.